Selective Phosphodiesterase 4B Inhibitors: A Review

Sci Pharm. 2014 Jun 10;82(3):453-81. doi: 10.3797/scipharm.1404-08. Print 2014 Jul-Sep.

Abstract

Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation. It has been demonstrated that this isoform is involved in the orchestra of events which includes inflammation, schizophrenia, cancers, chronic obstructive pulmonary disease, contractility of the myocardium, and psoriatic arthritis. Phosphodiesterase 4B has constituted an interesting target for drug development. In recent years, a number of PDE4B inhibitors have been developed for their use as therapeutic agents. In this review, an up-to-date status of the inhibitors investigated for the inhibition of PDE4B has been given so that this rich source of structural information of presently known PDE4B inhibitors could be helpful in generating a selective and potent inhibitor of PDE4B.

Keywords: Antiproliferative activity; Chronic obstructive pulmonary disease; Cyclic adenosine monophosphate; PDE4B; Phosphodiesterases (PDE) enzymes; Selective PDE inhibitors.

Publication types

  • Review